drugset
drugset / Trial / NCT07134088

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

NCT07134088 ↗

Phase 1/2 Active not recruiting 104 enrolled Amgen BeOne Medicines · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.

Timeline

Start
2025-12-08
Primary completion
2028-12-05
Completion
2030-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Blinatumomab Monoclonal antibody — Subcutaneous

Indications

B-cell acute lymphoblastic leukemia precursor B-cell acute lymphoblastic leukemia